|
|
SBAS2 |
|
Vaxjo ID |
378 |
|
Vaccine Adjuvant Name |
SBAS2 |
|
Alternative Names |
AS02 |
|
Adjuvant VO ID |
VO_0005529
|
|
Description |
saponin-based oil in water emulsion adjuvant that induces Th1 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
The Gambia |
|
Host Species for Testing |
Human |
|
Components |
50 μg monophosphoryl lipid A (MPL) and 50 μg Quillaja saponaria 21 (QS-21), 250 μl of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 ml |
|
Function |
strong antibody responses, strong effector cellular immune response (TH1 primarily) and DTH responses, as well as MHC class I restricted CTL responses |
| References |
Doherty et al., 1999: Doherty JF, Pinder M, Tornieporth N, Carton C, Vigneron L, Milligan P, Ballou WR, Holland CA, Kester KE, Voss G, Momin P, Greenwood BM, McAdam KP, Cohen J. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. The American journal of tropical medicine and hygiene. 1999; 61(6); 865-868. [PubMed: 10674660].
NCT01556945: Clinicaltrials.gov [https://www.clinicaltrials.gov/study/NCT01556945?term=SBAS2&rank=1]
|
|
